Scott Hensley
-
The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that appears to support its authorization for emergency use. -
The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.
-
Advisers to the Food and Drug Administration voted 20-0 to recommend that the agency authorize Moderna's vaccine for emergency use during the pandemic. There was a single abstention.
-
Two days before a panel of experts is set to review Moderna's COVID-19 vaccine and advise the Food and Drug Administration, documents show the vaccine is 94% effective and well-tolerated.
-
In a 17-4 vote, an expert committee concluded that the scientific evidence supports the authorization of the COVID-19 vaccine from Pfizer and BioNTech for emergency use during the pandemic.
-
The Food and Drug Administration finds "no specific safety concerns" that would stand in the way of authorization of the vaccine for emergency use. Effectiveness is 95% after two doses.
-
Watch an expert panel discussion on the effort to develop and deploy safe and effective vaccines against COVID-19 on Friday, Nov. 20, to be live-streamed here at 12 p.m. ET
-
The president, who is being treated for COVID-19, has been downplaying the severity of the disease. He said falsely that, compared with the flu, COVID-19 is "in most populations far less lethal."
-
The president says 50,000 could die from the flu. So far this season, the Centers for Disease Control and Prevention says, it's at least 23,000 with an upper estimate as high as 59,000.
-
How do Americans experience and cope with pain that makes everyday life harder? We asked in the latest NPR-IBM Watson Health Poll.
